Drug-drug interactions with imatinib: An observational study

Area of Science:

• Oncology
• Pharmacology
• Clinical Pharmacy

Background:

• Imatinib is a crucial cancer treatment medication.
• Concurrent medication use is common among imatinib recipients.
• Potential for drug-drug interactions (DDIs) poses a significant risk.

Purpose of the Study:

• To investigate the prevalence and nature of DDIs in patients undergoing imatinib therapy.
• To identify specific drugs commonly co-prescribed with imatinib that may interact.
• To provide evidence-based recommendations for managing DDIs during imatinib treatment.

Main Methods:

• Conducted two observational studies utilizing French health insurance and pharmacovigilance databases (2012-2015).
• Analyzed prescription data for 544 imatinib patients in the Midi-Pyrénées region.
• Reviewed adverse drug reaction reports for imatinib-associated DDIs.

Main Results:

• A high prevalence of potential DDIs was observed, with 89.3% of patients exposed to interacting drugs.
• Paracetamol, proton pump inhibitors, dexamethasone, and levothyroxine were frequently involved in potential DDIs.
• 40% of reported adverse drug reactions with imatinib involved potential DDIs.

Conclusions:

• A significant proportion of imatinib-treated patients are at risk of DDIs.
• Prescribers need heightened awareness of potential DDIs with imatinib.
• Recommendations include limiting paracetamol to 1300mg/day, avoiding dexamethasone, and doubling levothyroxine dosage when co-administered.